The Latest Cardiac and Vascular News
Internationally Recognized and Awarded Interventional Radiologist Enhances Depth of Expertise as the LIBERTY® Robotic System Races Towards Regularity and Commercialization Objectives HINGHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to experience a rising […]
Engagement with Interventional Radiologists Reaches Highest Level Yet as Company Continues to Progress Through Regulatory and Clinical Phases; Company Seeking to Create Interest and Anticipation for When the System is Commercialized HINGHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) — Microbot […]
Increases Key Opinion Leaders to 13 Throughout the Americas, Israel, and Europe to Support the Company’s Next Regulatory and Commercialization Paths for the LIBERTY® Robotic System HINGHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), today […]
Allows Endovascular Procedure to be Performed from the Cath-Lab Control Room, Potentially Minimizing Radiation Exposure and Reducing Physical Strain for the Healthcare Providers Design Patent Complements Existing U.S. and European Design Patents as Feedback During Recent Meetings Continues to Support […]
Advanced Features of Remote Controller Specifically Developed to Deliver an Enhanced User Experience During Endovascular Procedures HINGHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), in a continuation of its efforts to create barriers and expand […]
Corresponding Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its Novel Technology HINGHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) continues to aggressively protect its global […]
HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic System, the first disposable robotic system being developed for endovascular procedures. […]
Suspending Development of SCS and Evaluating Alternatives for SCS Assets HINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) has announced that, following the recent acquisition of the endovascular assets of Nitiloop Ltd. along with other […]
Integration with the LIBERTY® Robotic System & One & Done™ Technology May Enable Future Acceleration of Robotic Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Million Chronic Total Occlusion (CTO) Market1 through the Expansion of Robotic Ecosystem for Endovascular […]
Award-Winning Interventional Radiologist in the NY Metro Area Adds Significant Depth and Experience HINGHAM, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to be committed to expanding its capabilities, today announced the newest appointment […]
